Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIR9DW7SK)
  Drug Name Alfuzosin Drug Info Halofantrine Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Antimalarial Agents
  Structure

 Mechanism of Alfuzosin-Halofantrine Interaction (Severity Level: Major)
     Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Alfuzosin Halofantrine
      Mechanism Prolong QT interval Prolong QT interval
      Key Mechanism Factor 1
Factor Name QT interval
Factor Description Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
      Mechanism Description
  • Increased risk of prolong QT interval by the combination of Alfuzosin and Halofantrine 

Recommended Action
      Management Coadministration of halofantrine with other drugs that can prolong the QT interval is considered contraindicated.

References
1 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
2 Canadian Pharmacists Association.
3 Cerner Multum, Inc. "Australian Product Information.".
4 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
5 Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73. [PMID: 11432537]
6 Nosten F, ter Kuile FO, Luxemburger C, et al "Cardiac effects of antimalarial treatment with halofantrine." Lancet 341 (1993): 1054-6. [PMID: 8096959]
7 Product Information. Halfan (halofantrine). GlaxoSmithKline, Philadelphia, PA.
8 Product Information. Lariam (mefloquine). Roche Laboratories, Nutley, NJ.
9 Sudden death in a traveler following halofantrine administration--Togo, 2000. MMWR Morb Mortal Wkly Rep 50 (2001): 169-70, 179. [PMID: 11393488]